- ►bmj.com [PDF] CS Marsh, B Marden, R Newsom - British Medical Journal, 2004 - bjo.bmj.com Corticosteroid therapy, given orally or intravenously, is the standard treatment
for GCA associated visual loss. 1 The optimal route of administration and dosage
to pre- vent further visual loss are not known; however, most clinicians ... Cited by 26 - Related articles - All 8 versions
RL Keller, SEG Hamrick, JA Kitterman, JR … - Pediatric Critical Care Medicine, 2004 - journals.lww.com Objective: We describe a case of chronic pulmonary hypertension in a 7-wk-old
infant with congenital diaphragmatic hernia and an oral teratoma. Our patient
was dependent on low-dose inhaled nitric oxide and was still very unstable ... Cited by 36 - Related articles - All 7 versions
- Free from Publisher M Chaudhari, M Vogel, C Wright, J Smith, SG … - Archives of Disease in Childhood Fetal & Neonatal …, 2005 - critcaremed.org Halil Özgüç, MD; Nevzat Kahveci, MD, PhD; S¸ule Akköse, MD; Zehra Serdar,
MD; Veysel Balci, MD; Özgür Ocak, MD ... From the Department of Surgery
(HÖ), Physiology (NK), Emergency Medicine (SA, VB, ÖO), and Biochem- ... Cited by 14 - Related articles - BL Direct - All 7 versions
JN Travadi, SK Patole - Pediatric pulmonology, 2003 - interscience.wiley.com Persistent pulmonary hypertension of the newborn (PPHN) is a complex syndrome
with multiple causes, with an incidence of 0.43-6.8/1,000 live births and a
mortality of 10-20%. Survivors have high morbidity in the forms of ... Cited by 74 - Related articles - BL Direct - All 4 versions
A Saygılı, B Canter, E İriz, S Kula, FS … - Journal of cardiothoracic and vascular anesthesia, 2004 - Elsevier The use of inhaled nitric oxide (iNO) has become a part of therapy in patients
with PH over the last decade as its pulmonary selectivity has been clearly shown
in numerous cases.[1 and 2] The combination of iNO with other modulators of ... Cited by 12 - Related articles - All 8 versions
Z Kecskes, A Kent, G Reynolds - Journal of Maternal-Fetal and Neonatal Medicine, 2006 - informahealthcare.com Persistent pulmonary hypertension of the newborn (PPHN) remains an important
cause of mortality and morbidity in the term neonate. Underlying causes include
meconium aspiration syndrome, asphyxia, pulmonary hypoplasia, pneumonia, ... Cited by 6 - Related articles - BL Direct - All 6 versions
SA Lorch, A Cnaan, K Barnhart - Pediatrics, 2004 - Am Acad Pediatrics Results. The addition of iNO to the treatment regimen of PPHN increased the cost
of treating an infant by an average of $1141, primarily from an increased number
of mechanical ventilation days. Use of iNO led to 3.4% more lives saved and ... Cited by 20 - Related articles - BL Direct - All 7 versions
- ►critcaremed.org LS SHEKERDEMIAN, HB RAVN, DJ PENNY - Pediatric research, 2004 - journals.lww.com There has been recent interest in the use of the phosphodiester- ase-5 inhibitor
sildenafil for treating pulmonary hypertension. We examined the interaction
between inhaled nitric oxide (iNO) and iv sildenafil in 12 piglets with ... Cited by 43 - Related articles - BL Direct - All 6 versions
- ►nih.gov [PDF] CM Pierce, AJ Petros, AR Fielder - The British Journal of Ophthalmology, 2005 - pubmedcentral.nih.gov If you have a burning desire to respond to a paper published in the BJO, why not
make use of our ''rapid response'' option? Log on to our website
(www.bjophthalmol. com), find the paper that interests you, and send your ... Cited by 4 - Related articles - All 7 versions
PM Filan, PN McDougall, LS Shekerdemian - Journal of paediatrics and child health, 2006 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 5 - Related articles - BL Direct - All 4 versions
